ASNDAscendis Pharma A/S

Nasdaq ascendispharma.com


$ 136.77 $ -1.89 (-1.36 %)    

Thursday, 06-Jun-2024 11:05:59 EDT
QQQ $ 463.98 $ 0.30 (0.07 %)
DIA $ 388.79 $ 0.08 (0.02 %)
SPY $ 534.65 $ -0.32 (-0.06 %)
TLT $ 93.07 $ 0.19 (0.2 %)
GLD $ 218.91 $ 1.07 (0.49 %)
$ 138.5
$ 138.66
$ 0.00 x 0
$ 0.00 x 0
$ 135.60 - $ 138.66
$ 85.08 - $ 161.00
250,835
na
7.99B
$ 0.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ascendis-pharma-to-present-new-data-and-updated-results-from-phase-12-il-believe-trial-at-asco-2024

-  40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated...

 stifel-initiates-coverage-on-ascendis-pharma-with-buy-rating-announces-price-target-of-200

Stifel analyst Alex Thompson initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Targe...

 morgan-stanley-maintains-equal-weight-on-ascendis-pharma-raises-price-target-to-140

Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Equal-Weight and raises the price targe...

 fda-pushes-review-date-for-ascendis-pharmas-hormone-disorder-candidate-by-three-months

Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August ...

 cantor-fitzgerald-reiterates-overweight-on-ascendis-pharma-maintains-173-price-target

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $173 price target.

 fda-extends-review-period-for-ascendis-pharmas-transcon-pth-for-adults-with-hypoparathyroidism

Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024

 ascendis-pharma-announces-2-year-results-from-a-post-hoc-analysis-of-their-phase-3-pathway-trial-demonstrating-sustained-improvements-in-renal-function-in-adults-with-chronic-hypoparathyroidism-treated-with-transcon-pth

Ascendis Pharma A/S (NASDAQ:ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway ...

 ascendis-pharma-as-clinical-and-quality-of-life-data-for-transcon-pth-treated-adults-with-chronic-hypoparathyroidism-to-be-presented-at-ece-2024

Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and qual...

 wells-fargo-maintains-overweight-on-ascendis-pharma-raises-price-target-to-262

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from...

 jp-morgan-maintains-overweight-on-ascendis-pharma-raises-price-target-to-170

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $16...

 cantor-fitzgerald-reiterates-overweight-on-ascendis-pharma-maintains-173-price-target

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $173 price target.

 morgan-stanley-maintains-equal-weight-on-ascendis-pharma-maintains-116-price-target

Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Equal-Weight and maintains $116 price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION